Skip to main content
. 2020 Jun 1;20:503. doi: 10.1186/s12885-020-06958-3

Table 7.

Translational work-up

 • Tumor-infiltrating lymphocytes (TiL) repertoire determination from tumor
 • Liquid biopsy next-generation sequencing (NGS) immunoprofiling (TCRβ & IgH) before treatment initiation and before second cycle to determine response predictive immune signature (diversification pattern as read-out for ongoing immune activation, TiL clone expansion in peripheral blood)
 • In addition, FFPE will be centrally tested for PD-L1, HER2 (IHC and ISH), MSI, EBV and HER signaling alterations (amplifications and/or mutations in e.g. EGFR, HER2, HER3, PIK3CA) and correlated with clinical efficacy
 • CTC will be evaluated for changes in HER2 and PD-L1 status
 • ctDNA will be evaluated for HER signaling alterations (amplifications and/or mutations in e.g. EGFR, HER2, HER3, PIK3CA)
 • Central imaging review and determination of ORR and PFS according to modified RECIST